This growth was bolstered by strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. In light of these results, the company ...

This growth was bolstered by strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. In light of these results, the company ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.